Brookline Capital Markets Weighs in on CRDL Q3 Earnings

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Brookline Capital Markets reduced their Q3 2026 EPS estimates for Cardiol Therapeutics in a note issued to investors on Wednesday, April 1st. Brookline Capital Markets analyst F. Ahmed now anticipates that the company will post earnings of ($0.08) per share for the quarter, down from their previous estimate of ($0.07). The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.33) per share. Brookline Capital Markets also issued estimates for Cardiol Therapeutics’ Q4 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.31) EPS.

A number of other research firms have also recently commented on CRDL. HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Cardiol Therapeutics in a research note on Tuesday, February 10th. Wall Street Zen raised shares of Cardiol Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday. upgraded Cardiol Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 3rd. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $8.00 target price on shares of Cardiol Therapeutics in a report on Monday. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $8.50.

Cardiol Therapeutics Stock Down 0.4%

Cardiol Therapeutics stock traded down $0.01 during midday trading on Tuesday, reaching $1.39. The company’s stock had a trading volume of 529,314 shares, compared to its average volume of 545,432. Cardiol Therapeutics has a 52-week low of $0.80 and a 52-week high of $1.59. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.89 and a quick ratio of 3.89. The stock has a market capitalization of $154.87 million, a P/E ratio of -4.95 and a beta of 0.82. The stock’s 50-day simple moving average is $1.06 and its 200-day simple moving average is $1.05.

Cardiol Therapeutics (NASDAQ:CRDL) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.04.

Institutional Trading of Cardiol Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Security National Bank of Sioux City Iowa IA purchased a new stake in Cardiol Therapeutics during the 4th quarter worth approximately $31,000. Simplex Trading LLC lifted its holdings in Cardiol Therapeutics by 96.9% in the 4th quarter. Simplex Trading LLC now owns 32,197 shares of the company’s stock valued at $31,000 after purchasing an additional 15,842 shares in the last quarter. Boyer Financial Services Inc. acquired a new stake in shares of Cardiol Therapeutics in the fourth quarter valued at about $33,000. Bank of America Corp DE lifted its stake in shares of Cardiol Therapeutics by 136.2% in the second quarter. Bank of America Corp DE now owns 26,455 shares of the company’s stock worth $36,000 after buying an additional 15,255 shares in the last quarter. Finally, Susquehanna International Group LLP boosted its position in Cardiol Therapeutics by 366.5% during the third quarter. Susquehanna International Group LLP now owns 93,398 shares of the company’s stock worth $100,000 after acquiring an additional 73,375 shares during the last quarter. Hedge funds and other institutional investors own 12.49% of the company’s stock.

Cardiol Therapeutics News Roundup

Here are the key news stories impacting Cardiol Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $9.00 price target, and materially tightened/raised its EPS outlook — forecasting quarter-by-quarter EPS of ($0.06) and raising FY2026 to ($0.27) (from $0.41) and FY2027 to ($0.34) (from $0.51). Those upward revisions and the high price target are constructive for sentiment. MarketBeat: HC Wainwright Estimates
• Positive Sentiment: Canaccord Genuity reaffirmed its “Buy” rating and set an $8.00 target, reiterating bullish analyst support and providing an additional near-term catalyst for buyers. Benzinga: Canaccord Reaffirmation
• Neutral Sentiment: Consensus full‑year EPS expectations remain negative (around ($0.33) per share), so despite analyst activity the company is still expected to report losses — this limits how strongly upgrades will translate to valuation changes. MarketBeat: Consensus Estimates
• Negative Sentiment: Brookline Capital Markets trimmed near-term and full‑year EPS forecasts (Q3 to ($0.08) from ($0.07), Q4 to ($0.09), and FY2026 to ($0.31) from ($0.29)), a downgrade that introduces downward pressure and highlights execution/forecast risk. MarketBeat: Brookline Estimate Cuts

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.